Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 5/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | CCR1 | P32246 | 1/20 | 0.32 |
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
| ▸ | CCR8 | P51685 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18246523 | 0.81 | APLNR (1.00) | APLNRATMCCR1CCR5CCR8 | |
| SCHEMBL18246176 | 0.81 | APLNR (1.00) | APLNRATMCCR1CCR5CCR8 | |
| SCHEMBL18474514 | 0.81 | APLNR (1.00) | APLNRATMCCR1CCR5CCR8 | |
| SCHEMBL19550838 | 0.81 | APLNR (1.00) | APLNRATMCCR1CCR5CCR8 | |
| SCHEMBL18246399 | 0.81 | APLNR (1.00) | APLNRATMCCR1CCR5CCR8 | |
| SCHEMBL22812895 | 0.81 | APLNR (1.00) | APLNRATMCCR1CCR5CCR8 | |
| SCHEMBL24080199 | 0.80 | APLNR (0.55) | APLNRCCR1CCR5CCR8HDAC6 | |
| SCHEMBL15274514 | 0.80 | APLNR (0.67) | APLNRMAPK1ATMCCR1CCR5 | |
| SCHEMBL12457569 | 0.80 | APLNR (0.67) | APLNRMAPK1ATMCCR1CCR5 | |
| SCHEMBL27463869 | 0.80 | APLNR (0.67) | APLNRMAPK1ATMCCR1CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018093579-A1 | TRIAZOLE PHENYL COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2018-05-24 | — | — | WO | disclosed |